SEARCH

SEARCH BY CITATION

References

  • Adamis AP, Altaweel M, Bressler NM et al. (2006): Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113: 2328.
  • Ahmadieh H, Ramezani A, Shoeibi N et al. (2008): Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246: 483489.
  • Ahmadieh H, Shoeibi N, Entezari M & Monshizadeh R (2009): Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 116: 19431948.
  • Arevalo JF, Maia M, Flynn HW Jr et al. (2008): Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92: 213216.
  • Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J & Rodriguez FJ (2009a): Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 247: 735743.
  • Arevalo JF, Sanchez JG, Wu L et al. (2009b): Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116: 14881497, 1497 e1.
  • Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF & Evans T (2009c): Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond) 23: 117123.
  • Avery RL, Pearlman J, Pieramici DJ et al. (2006): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695 e1e15.
  • Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP & Schneider S (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 14321444.
  • Chen E, Hsu J & Park CH (2009): Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 40: 6870.
  • Cho WB, Oh SB, Moon JW & Kim HC (2009): Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 29: 516522.
  • Chun DW, Heier JS, Topping TM, Duker JS & Bankert JM (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113: 17061712.
  • Cunningham ET Jr, Adamis AP, Altaweel M et al. (2005): A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 17471757.
  • da R Lucena, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL & Jorge R (2009): Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 93: 688691.
  • Diabetic Retinopathy Vitrectomy Study Research group (1990): Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 108: 958964.
  • Early Treatment Diabetic Retinopathy Study Research group (1985): Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 17961806.
  • Early Treatment Diabetic Retinopathy Study Research Group (1991): Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98: 766785.
  • Elman MJ, Aiello LP, Beck RW, et al. (2010): Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 10641077.e35.
  • Erdol H, Turk A, Akyol N & Imamoglu HI (2010): The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina 30: 570577.
  • Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N & Faghihi S (2008): Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 18: 941948.
  • Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL III & Klein R (2004): Retinopathy in diabetes. Diabetes Care 27(Suppl 1): S84S87.
  • Hansen LL,Resolve Study Group. Visual Acuity Response to Ranibizumab Treatment Based on Baseline Characteristics of Diabetic Macular Edema Patients in the RESOLVE Study. Presented at 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 2 to May 6, 2010; Fort Lauderdale, FL. Abstarct #5841.
  • Huang YH, Yeh PT, Chen MS, Yang CH & Yang CM (2009): Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 29: 11341140.
  • Jorge R, Costa RA, Calucci D, Cintra LP & Scott IU (2006): Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26: 10061013.
  • Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A & Haritoglou C (2008): Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 28: 10531060.
  • Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S & Li CL (2009): Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 29: 292299.
  • di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT & Romano MR.(2010): Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248: 785791.
  • Michaelides M, Kaines A, Hamilton RD et al. (2010): A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study): 12-Month Data Report 2. Ophthalmology 117: 10781086.e2.
  • Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A & Faghihi H (2008): Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 18: 263269.
  • Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M & Parvaresh MM (2009): Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 19: 848852.
  • Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH & Azarmina M (2008): Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246: 16991705.
  • Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P & Campochiaro PA (2009): Primary end point (six months) results of the Ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116: 21752181. e1.
  • Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M & Tano Y (2009): Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 116: 927938.
  • Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU & Jorge R (2008): Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92: 7680.
  • Querques G, Bux AV, Martinelli D, Iaculli C & Noci ND (2009): Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 87: 623630.
  • Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S & Williams G (2008): Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246: 837842.
  • Romano MR, Gibran SK, Marticorena J, Wong D & Heimann H (2009a): Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye (Lond) 23: 16981701.
  • Romano MR, Gibran SK, Marticorena J, Wong D & Heimann H (2009b): Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? Eur J Ophthalmol 19: 618621.
  • Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY & Kim RY (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 14191431.
  • Schmidinger G, Maar N, Bolz M, Scholda C & Schmidt-Erfurth U (2009): Repeated intravitreal bevacizumab (Avastin(R)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol [Epub ahead of print].
  • Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T & Nishida K (2008): Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145: 854861.
  • Soheilian M, Ramezani A, Obudi A et al. (2009): Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116: 11421150.
  • The Diabetic Retinopathy Clinical Research Network (2008): A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115: 14471449, 1449 e1–10.
  • The Diabetic Retinopathy Clinical Research Network. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Presented at the association for research in vision and ophthalmology (ARVO) meeting 2010, Fort Lauderdale, Florida, USA
  • The Diabetic Retinopathy Study Research Group (1981): Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 88: 583600.
  • Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU & Jorge R (2008): Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 86: 385389.
  • Waisbourd M, Loewenstein A, Goldstein M & Leibovitch I (2007): Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 24: 643662.
  • Yeh PT, Yang CM, Lin YC, Chen MS & Yang CH (2009): Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 29: 768774.